News | May 30, 2014

CardiAQ Reports Successful First-in-Human Transapical Implantation of its Second-Generation Valve

May 30, 2014 — CardiAQ Valve Technologies announced it successfully implanted its second-generation transcatheter mitral valve (TMVI) using the company’s newly added transapical delivery system. CardiAQ previously performed the first ever transfemoral transcatheter mitral valve implantation procedure in June 2012 with its self-conforming, self-anchoring implant technology. The transapical TMVI procedure was performed on an 88-year-old female suffering from severe mitral regurgitation (MR 4+) at The Heart Centre, Rigshospitalet University Hospital, Copenhagen, Denmark, by interventional cardiologists Lars Søndergaard, M.D., echocardiographer Nikolaj Ihlemann, M.D., cardiothoracic surgeons Peter Skov Olsen, M.D., Susanne Holme, M.D., and Arshad Quadri, M.D., and anesthesiologist Peter Bo Hansen, M.D.

“We are grateful to have had the opportunity to work with the CardiAQ technology again in order to provide treatment to this patient for whom no other alternatives were available,” said Søndergaard. “Based on a number of risk and anatomical factors, neither traditional mitral valve surgery nor transcatheter repair with MitraClip were options for this patient. Through careful review and consideration, we determined that TMVI, using CardiAQ’s second-generation transcatheter mitral valve and its new transapical delivery system, could offer this patient a chance at a longer and more comfortable life. The valve was implanted successfully with excellent function. The patient is recovering uneventfully and already feels a marked reduction in symptoms.”

“CardiAQ’s second-generation transcatheter mitral valve builds upon the company’s proprietary method for anchoring the implant through leaflet engagement, chordal preservation and annular attachment, while offering greater durability, improved flow properties and a novel feature for the prevention of paravalvular leaks,” said Arshad Quadri, M.D., founder and CMO of CardiAQ Valve Technologies.

“In the past few years, the potential of TMVI has become increasingly clear. As the first company to utilize the subvalvular apparatus in our attachment method, CardiAQ has set the standard for TMV anchoring,” said Brent Ratz, co-founder, president and COO of CardiAQ. “With the benefit of our first-generation first-in-human experience in 2012, we have gone on to further optimize our implant, incorporating all that we have learned into our second-generation TMV technology.”

For more information: www.cardiaq.com

Related Content

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Overlay Init